Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl4-induced liver fibrosis

Baode Shen; Li Deng; Yuan Liu; Ruisheng Li; Chengying Shen; Xiao Liu; Yinchao Li; Hailong Yuan

doi:10.1016/j.chmed.2021.09.013

Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl₄-induced liver fibrosis

Chin Herb Med. 2021 Dec 21;14(1):104-110. doi: 10.1016/j.chmed.2021.09.013. eCollection 2022 Jan.

Authors

Baode Shen¹, Li Deng^{2

3}, Yuan Liu¹, Ruisheng Li⁴, Chengying Shen¹, Xiao Liu¹, Yinchao Li², Hailong Yuan¹

Affiliations

¹ Department of Pharmacy, Air Force Medical Center, PLA, Beijing 100142, China.
² College of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
³ School of Chemistry, Biology and Material Science, East China University of Technology, Nanchang 330013, China.
⁴ Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing 100039, China.

Abstract

Objective: Fufang Biejia Ruangan Tablet (FBRT) is widely used for the treatment of liver fibrosis. However, Hominis Placenta (HP), as an important adjuvant of FBRT, has been restricted for medicinal using due to the limited availability, ethical controversy and safety issues. The present study aimed to investigate the therapeutic effects of novel FBRT (N-FBRT) with sheep placenta (SP) as substitute for HP on liver fibrosis and explore its possible mechanisms. Different dosages of SP in N-FBRT were also evaluated.

Methods: Rats were subcutaneously injected with CCl₄ to induce liver fibrosis and then treated with N-FBRT and FBRT. The anti-hepatic fibrosis effect was determined based on biomarkers analysis of liver function and hepatic fibrosis, and the liver pathology was visualized by H&E staining and Masson staining. The oxidative stress and inflammatory cytokines were also detected. Immunohistochemical staining of α-SMA, real time PCR and Western blotting were performed to evaluate hepatic stellate cells (HSCs) activation and TGF-β1/Smad signaling pathway.

Results: N-FBRT and FBRT could ameliorate CCl₄-induced liver fibrosis and improve liver function, as evidenced by lowering serum biomarkers levels of liver function and hepatic fibrosis, and decreasing hepatic Hyp content and collagen deposition, and improving the hepatic morphology and architecture changes. Moreover, the anti-liver fibrosis effect was better when the dosage of SP used in N-FBRT was 1/2 of HP in FBRT. Administration of N-FBRT markedly alleviated oxidative stress and inflammatory cytokines, and inhibited α-SMA expression. Furthermore, the mRNA expression of Col I, Col III, α-SMA and TGF-β1, and proteins expression of α-SMA, TGF-β1, Smad2/3 and p-Smad2/3 were significantly down-regulated by N-FBRT treatment.

Conclusion: SP can be used as substitute for HP to prepare N-FBRT for the treatment of liver fibrosis and the anti-liver fibrosis effect of N-FBRT is achieved by eliminating oxidative stress and inflammation, and inhibiting HSCs activation and ECM production by blocking TGF-β1/Smad signaling pathway.

Keywords: Fufang Biejia Ruangan Tablet; Hominis Placenta; TGF-β1/Smad signaling pathway; liver fibrosis; sheep placenta; substitute.